Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care. (Dej@lo)
This study aims to evaluate the effectiveness of an intervention to help people to quit smoking throughout an chat bot compared with usual assistance to increase long-term rates of nicotine abstinence in smoking outpatients with biochemical validation at 6 months.
Half of participants(control group) will receive usual care by their usual general practitioners and nurses, and the other half (intervention group) will use an evidence-based chat bot specifically designed to help people quit smoking.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
An array of interventions have been shown to be both cost-effective and efficacious in helping patients quit smoking and so are included in usual care given by general practitioners and nurses. However, in the primary care setting, this sort of interventions are less common than they should be, due to many circunstances, and solutions must be found due to the huge dimensions of tobacco use challenge.
On the other hand,new kinds of information tecnology give a chance to intervene with less costs and more specific tools. Actually, there are a lot of mobile apps and other devices designed to help people to improve their health in many ways, but without scientific evidence of their effects.
This is a pragmatic, randomised, controled and multicentric clinical trial that tries to evaluate in general population the effectiveness of a chat bot that incorporates evidence based interventions and interacts by a text application instaled in patients mobile phone (intervention group).
Investigators have decided to compare with usual care delivered by the usual general practisioners and nurses of Spanish Public Health Centres, because this interventions have shown their effectiveness (control group).
Efficiency and impact on quality of life will also be compared on both groups.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28924
- Eduardo Olano-Espinosa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or more
- Smoked more than one cigarette per day last month.
- Accepts help to quit smoking next month.
- Owns a mobile phone with the ability to install a messaging application.
- Does not anticipate changing address in the next 6 months.
- Understands spoken and written spanish language.
- Accepts to participate and signs the informed consent.
Exclusion Criteria:
- Communicative barriers.
- Addiction to other substances.
- Participation in another cessation program or other clinical trial during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
Use of an evidence-based chat bot for smoking cessation
|
Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
Other Names:
|
|
Active Comparator: Control
Usual care (Madrid Health System Portfolio).
|
Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Continuous tobacco abstinence at six months biochemically validated
Time Frame: Six months
|
Patient declares to have smoked less than five cigarettes in the last six months and have less than 10 parts per million (ppm) of carbon monoxide in exhaled air measured by a Pico+TM Smokerlyzer® cooximeter
|
Six months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Continuous tobacco abstinence at six months referred by patient
Time Frame: Six months
|
Patient declares to have smoked less than five cigarettes in the last six months
|
Six months
|
|
Descriptive improvement in patient´s quality of life
Time Frame: Six months
|
EuroQol 5D-5L questionary score descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Patient is asked to indicate health state by ticking the box next to the most appropriate statement in each dimension.
This results in a 1-digit number that expresses the level selected for that dimension.
Digits can be combined into a 5-digit number that describes the patient's health state.
|
Six months
|
|
Sujective improvement in patient´s quality of life
Time Frame: Six months
|
EuroQol 5D-5L questionary score visual analogue scale (EQ VAS). EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. Can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
Six months
|
|
QALYs
Time Frame: Six months
|
Quality-adjusted life years
|
Six months
|
|
Number of therapeutic contacts
Time Frame: Six months
|
Number of contacts (therapist-patient or bot-patient) during the therapeutic process
|
Six months
|
|
Time spent in therapy
Time Frame: Six months
|
Total amount of time spent (in minutes) during the therapeutic process
|
Six months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: José F Ávila-Tomás, Doctor, GAP Madrid
- Study Chair: Francisco J Ayesta-Ayesta, Doctor, Cantabria University
- Study Chair: Francisco J Martínez-Suverbiola, Doctor, GAP Madrid
Publications and helpful links
General Publications
- Olano-Espinosa E, Avila-Tomas JF, Minue-Lorenzo C, Matilla-Pardo B, Serrano Serrano ME, Martinez-Suberviola FJ, Gil-Conesa M, Del Cura-Gonzalez I; Dejal@ Group. Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care. JMIR Mhealth Uhealth. 2022 Jun 27;10(6):e34273. doi: 10.2196/34273.
- Avila-Tomas JF, Olano-Espinosa E, Minue-Lorenzo C, Martinez-Suberbiola FJ, Matilla-Pardo B, Serrano-Serrano ME, Escortell-Mayor E; Group Dej@lo. Effectiveness of a chat-bot for the adult population to quit smoking: protocol of a pragmatic clinical trial in primary care (Dejal@). BMC Med Inform Decis Mak. 2019 Dec 3;19(1):249. doi: 10.1186/s12911-019-0972-z.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- P17/01942
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use Cessation
-
NCT07431619Not yet recruitingTobacco Cessation
-
NCT06637358CompletedSmokeless Tobacco Cessation
-
NCT03238456CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Cigarette
-
NCT03645941CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, Cigarette
-
NCT03227679CompletedTobacco Use | Tobacco Use Cessation
-
NCT06098144RecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use Cessation
-
NCT06438549RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in Childbirth
-
NCT07148232RecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco Abstinence
-
NCT03671707CompletedSmoking Cessation | Tobacco Use Cessation
-
NCT01699828CompletedSmoking Cessation | Tobacco Use Cessation
Clinical Trials on Chat bot
-
NCT07079306Not yet recruitingSmoking Cessation
-
NCT06346496CompletedDepression | Anxiety | LLM-based AI Dialogue Bot
-
NCT03686917Completed
-
NCT04479969CompletedChronic Obstructive Pulmonary Disease
-
NCT05890313Not yet recruitingCognitive Dysfunction | Mild Cognitive Impairment
-
NCT05884697Active, not recruitingPapillomavirus Vaccines | Human Papillomavirus Viruses
-
NCT03648164CompletedHealth Behavior | Well Being
-
NCT00906737Completed